Labeling Update Alert: Librela® (bedinvetmab injection), NADA 141-562
Labeling Update Alert: Librela® (bedinvetmab injection), NADA 141-562 Overview Librela® (bedinvetmab injection), the first monoclonal antibody approved in the U.S. to control osteoarthritis pain in dogs, received important label updates on February 18, 2025, under NADA 141-562. These changes reflect data gathered from real-world post-approval use since its U.S. launch in October 2023. [...]